Weekly changes in body weight and body composition.

<p>(A) Body weight increased by week 2 and remained elevated throughout the six-week hypercaloric high-fat feeding period. (B) Visceral (white bar) and subcutaneous (black bar) adipose tissue calculated as area percent of total tissue. *P<.05 vs. week0; **P<.01 vs. week 0; ***P<.001 vs. week 0.</p

Consistency of the hyperbolic relationship (DI) between insulin sensitivity and insulin secretion.

<p>Solid black hyperbolic curve =  average DI value for week 0; black solid square  =  average DI for week 0; open square  =  average DI for week 2; black solid triangle  =  average DI for week 4; open triangle  =  average DI for week 6. The hyperbola represents the curve on which the animals would have to remain to maintain a constant DI (DI = AIRg.SI = constant) and it is calculated as extrapolation of the average DI for week 0 over a range of insulin sensitivities.</p

Glucose and FFA plasma levels at three time periods during 24-hr before and after fat feeding.

<p>(A) Plasma glucose and (B) plasma FFAs during 2–4 AM (hash bars), 8–8:30 AM (black bars), and 6–8 PM (white bars). *P<.05 vs. week0; **P<.01 vs. week 0; ***P<.001 vs. week 0.</p

Spearman’s rank correlation between fasting insulin and fasting FFA.

<p>Spearman’s rank correlation between fasting insulin and fasting FFA.</p

Observed fasting plasma insulin, glucose and FFAs.

<p>Fasting levels of (A) insulin, (B) glucose, and (C) FFA before and after fat feeding. *P<.05 vs. week0; **P<.01 vs. week 0; ***P<.001 vs. week 0.</p

Weekly estimates of insulin sensitivity, insulin secretion and whole-body insulin clearance.

<p>(A) SI, (B) AIRg, and (C) MCR of insulin. *P<.05 vs. week 0; **P<.01 vs. week 0; ***P<.001 vs week 0.</p

Changes in metabolic parameters after exenatide treatment for 12 weeks in pre-diabetic canines.

<p>Changes in metabolic parameters after exenatide treatment for 12 weeks in pre-diabetic canines.</p

Primers and probes used for RT-PCR.

<p>Primers and probes used for RT-PCR.</p

Effect of exenatide on oral glucose tolerance.

<p>Compared with placebo (n = 7), exenatide (n = 7) was not different in modifying AUC_GLUCOSE (A and B), AUC_INSULIN (C and D) or AUC_GLUCAGON (E and F). Continuous red and blue lines indicate exenatide and placebo groups, respectively, after 12 weeks. Dash red and blue lines indicate exenatide and placebo groups, respectively, at baseline (week 0). B, D, and F show the nonlinear fits (polynomial of third order) for curves represented in A, C, and E, respectively. Plots are medians. Bars are upper and lower quartiles. Glucagon data were available only in 6 dogs.</p

Changes in food intake and body composition after exenatide treatment for 12 weeks in pre-diabetic canines.

<p>Changes in food intake and body composition after exenatide treatment for 12 weeks in pre-diabetic canines.</p